Crescent Biopharma Income Statement (2013-2026) | CBIO

Income Statement Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.06M142.000.09M0.02M0.07M-1.07M1.04M
Operating items
Research & Development (Quarter)
11.15M10.17M13.28M12.90M9.60M7.97M4.92M5.89M5.42M4.07M5.29M5.29M6.03M6.29M2.47M0.01M12.08M20.35M78.20M17.90M
Selling, General & Administrative (Quarter)
4.19M4.24M4.14M4.55M5.06M5.45M3.84M4.73M5.52M4.86M4.52M4.31M5.09M4.07M0.16M2.38M8.95M5.54M7.31M7.87M
Other Operating Expenses (Quarter)
1.22M16.83M
Operating Expenses (Quarter)
15.34M14.40M17.42M17.44M14.66M13.43M8.77M10.62M10.94M8.93M9.81M9.60M11.12M10.36M2.63M2.40M21.03M25.89M102.34M25.77M
Operating Income (Quarter)
-14.28M-14.40M-17.34M-17.43M-14.66M-13.35M-8.77M-10.62M-10.94M-8.93M-9.81M-9.59M-11.12M-10.36M-2.63M-2.40M-21.03M-25.89M-91.49M-24.73M
EBIT (Quarter)
-14.28M-14.40M-17.34M-17.43M-14.66M-13.35M-8.77M-10.62M-10.94M-8.93M-9.81M-9.59M-11.12M-10.36M-2.63M-2.40M-21.03M-25.89M-91.49M-24.73M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M0.00M0.00M0.01M0.09M0.24M0.38M0.58M0.67M0.61M0.51M0.38M0.26M0.06M0.31M1.28M1.09M1.45M
Other Non Operating Income (Quarter)
-0.76M1.28M1.45M
Non Operating Income (Quarter)
0.61M0.51M-0.76M1.28M-0.28M1.45M
Net income details
EBT (Quarter)
-14.27M-14.40M-17.33M-17.42M-14.65M-13.27M-8.52M-10.24M-10.36M-8.26M-9.20M-9.08M-10.74M-10.10M-2.63M-2.34M-21.79M-24.61M-90.40M-23.28M
Tax Provisions (Quarter)
Profit After Tax (Quarter)
-14.27M-14.40M-17.33M-17.42M-14.65M-13.27M-8.52M-10.24M-10.36M-8.26M-9.20M-9.08M-10.74M-10.10M-2.63M-15.15M-21.79M-24.60M-92.44M-23.28M
Income from Continuing Operations (Quarter)
-14.27M-14.40M-17.33M-17.42M-14.65M-13.27M-8.52M-10.24M-10.36M-8.26M-9.20M-9.08M-10.74M-10.10M-2.63M-2.34M-21.79M-24.61M-90.40M-23.28M
Consolidated Net Income (Quarter)
-14.27M-14.40M-17.33M-17.42M-14.65M-13.27M-8.52M-10.24M-10.36M-8.26M-9.20M-9.08M-10.74M-10.10M-2.63M-2.34M-21.79M-24.61M-90.40M-23.28M
Income towards Parent Company (Quarter)
-14.27M-14.40M-17.33M-17.42M-14.65M-13.27M-8.52M-10.24M-10.36M-8.26M-9.20M-9.08M-10.74M-10.10M-2.63M-2.34M-21.79M-24.61M-90.40M-23.28M
Net Income towards Common Stockholders (Quarter)
-14.27M-14.40M-17.33M-17.42M-14.65M-13.27M-8.52M-10.24M-10.36M-8.26M-9.20M-9.08M-10.74M-10.10M-2.63M-2.34M-21.79M-24.61M-90.40M-23.28M
Additional items
EPS (Basic) (Quarter)
-0.28-0.28-0.34-0.33-0.28-0.25-0.16-0.19-0.17-0.13-0.14-0.14-0.17-0.16-0.15-0.04-1.57-1.77-3.28-0.84
EPS (Weighted Average and Diluted) (Quarter)
-0.28-0.28-0.34-0.33-0.28-0.25-0.16-0.19-0.17-0.13-0.14-0.14-0.04-0.16-0.15
Shares Outstanding (Weighted Average) (Quarter)
50.70M51.12M51.56M51.45M52.33M52.41M52.39M52.53M60.35M64.28M62.99M63.34M64.46M64.48M64.48M64.52M13.89M13.89M27.56M27.57M
Shares Outstanding (Diluted Average) (Quarter)
50.70M51.54M51.56M51.45M52.33M52.41M52.39M52.53M64.46M64.28M64.35M63.34M64.52M64.47M64.48M
EBITDA (Quarter)
-14.28M-14.40M-17.34M-17.43M-14.66M-13.35M-8.77M-10.62M-10.94M-8.93M-9.81M-9.59M-11.12M-10.36M-2.63M-2.40M-21.79M-24.61M-92.40M-23.28M
Interest Expenses (Quarter)
1.07M
Tax Rate (Quarter)